Reduced penetrance in human inherited disease

Egyptian Journal of Medical Human Genetics

Volumn 15, Issue 2, 2014, Pages 103-111

  Shawky, Rabah M ^a  

^a AIN SHAMS UNIVERSITY   (Egypt)

Author keywords

Copy number variations; Digenic inheritance; Environmental factors; Epigenetics; Expressivity; Modifier genes; Oligogenic inheritance; Penetrance

Indexed keywords

AGING; COPY NUMBER VARIATION; EPIGENETICS; GENE EXPRESSION; GENE MUTATION; GENETIC DISORDER; GENETIC VARIABILITY; GENOTYPE ENVIRONMENT INTERACTION; HUMAN; MODIFIER GENE; MOLECULAR GENETICS; MUTATIONAL ANALYSIS; PENETRANCE; REVIEW; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84897838100     PISSN: 11108630     EISSN: 20902441     Source Type: Journal    
DOI: 10.1016/j.ejmhg.2014.01.003     Document Type: Review

References (104)

1. Cooper D.N., Krawczak M. Where genotype is not predictive of phenotype: towards an understanding of the molecular basis of reduced penetrance in human inherited disease. Human Genet 2013, 132:1077-1130.
2. Vytopil M., Ricci E., Dello Russo A., Hanisch F., Neudecker S., et al. Frequent low penetrance mutations in the Lamin A/C gene, causing Emery Dreifuss muscular dystrophy. Neuromuscular Disorder 2002, 12:958-963.
3. Hung C., Lin S., Lee C., Chen C., Lin S., et al. Low penetrance of retinoblastoma for p. V654L mutation of the RB1 gene. BMC Med Gen 2011, 12:76-79.
4. Lobo I. Same genetic mutation, different genetic disease phenotype. Nature Educ 2008, 1(7):64.
5. Shawky R.M., Abd-Elkalek H.S., Gad S., Mohammad S.A., Seifeldin N.S. Cornelia-de-lange syndrome in an Egyptian infant with unusual bone deformities. Egypt J Med Hum Genet 2013, 14(1):109-112.
6. Shawky R.M., Elsayed S.M., Abd-Elkhalek H.S., Gad S. Oral-facial-digital syndrome type II: transitional type between Mohr and Varadi. Egypt J Med Hum Genet 2013, 14(3):311-315.
7. Shawky R.M., Elsayed S.M., Abd-Elkhalek H.S., Gad S. Familial Peters Plus syndrome with absent anal canal, sacral agenesis and sensorineural hearing loss: expanding the clinical spectrum. Egypt J Med Hum Genet 2013, 14(4):423-428.
8. Shawky RM, Elsayed SM, Abd-Elkhalek HS, Gad S. Intrafamilial variability in simpson-Golabi-Behmel syndrome with bilateral posterior ear lobule creases. Egypt J Med Hum Genet 2014;15(1):87-90.
9. Xue Y., Chen Y., Ayub Q., Huang N., Ball E.V., et al. Deleterious - and disease allele prevalence in health individuals: insights from current predictions, mutations, mutation databases and population - scale resequencing. Am J Hum Genet 2012, 91:1022-1032.
10. Zlotogora J. Penetrance and expressivity in the molecular age. Genet Med. 2003, 5(5):347-353.
11. Burden K.P., Wirth M.G., Mackey D.A., Russell-Eggitt I.M., Craig J.E., et al. A novel mutation in the connexin 46 gene autosomal dominant congenital cataract with incomplete penetrance. J Med Genet 2004, 41:e 106.
12. Saini S., Robinson P.N., Singh J.R., Vanita V. A novel 7 bp deletion PRPF31 associated with autosomal dominant retinitis pigmentosa with incomplete penetrance in an Indian Family. Exp Eye Res 2012, 104:82-88.
13. Mathias A., Moss A.J., Lopes C.M., Barsheshet A., MeNitt S., et al. Prognostic implications of mutation specific QTc standard deviation in congenital long QT syndrome. Heart Rythm 2013, 10:720-725.
14. Beutler E. The HEF, Cys 282 Tyr mutation as a necessary but not sufficient cause of clinical hereditary hemochromatosis. Blood 2003, 101:3347-3350.
15. Fairly C., Zimran A., Phillps M., Cizmarik M., Yee J., et al. Phenotypic heterozygosity of N3705 homozygotes with type I Gancher disease: an analysis of 798 patients from ICGG Gaucher Registry. J Inherit Metabol Dis 2008, 31:738-744.
16. Emery A.E.H. Risk estimation in autosomal dominant disorder, with reduced penetrance. J Med Genet 1918, 23:316.
17. Benson D.W., Sharkey A., Fatkin D., Lang P., et al. Clinical investigation and reports. Cerculation 1998, 97:2043-2048.
18. Sidransky E. Heterozygosity for a Mendelian disorder as a risk factor for complex disease. Clin Genet 2006, 70:275-282.
19. Thauvin - Robinet C., Munck A., Huet F., Genin E., Bellis G., et al. The very low penetrance of cystic fibrosis for the R117 H mutation: a reappraisal for genetic counselling and newborn screening. J Med Genet 2009, 46(11):752-758.
20. Bolk S., Pelet A., Hofstra R.M.W., Angrish M., Salomon R., Croaker D., et al. A human model for multigenic inheritance. Phenotypic expression in Hirschsprung disease requires both the RET gene and a new 9q31 locus. PNAS 1997, 1:268-273.
21. Onadin Z., Hogg A., Baird P.N., Cowell J.K. Oncogenic point mutations in exon 20 of the RBI gene in families showing incomplete penetrance and mild expression of the retinoblastoma phenotype. Proc Natl Acad Sci 1992, 89:6177-6181.
22. Arnold W.V., Fertala A. Skeletal diseases caused by mutations that affect collagen structure and function. Int J Biochem Cell Biol 2013, 45:1556-1567.
23. Austin E.D., Phillips J.A., Cogan J.D., Hamid R., Yu C., et al. Truncating and missense BMPR2 mutations differentially affect the severity of heritable pulmonary arterial hypertension. Respir Res 2009, 10:87.
24. Azaiez H., Chamberlin G.P., Fischer S.M., Weep C.L., Parasad S.D., et al. GJB 2: the spectrum of deafness- causing allele variants and their phenotype. Hum Mutat 2004, 24:305-311.
25. Aganna E., Aksentijevich I., Hitman G.A., Kastner D.L., et al. Tumor necrosis factor receptor-associated periodic syndrome (TRAPS) in a Dutch family - evidence for a TNFRSFIA mutation with reduced penetrance. Eur J Hum Genet 2001, 9-63-66.
26. Soriana A., Manna R. Familial Mediterranean fever: new phenotypes. Autoimmun Rev 2012, 12:13-37.
27. Panegyres R.K., Goh J.G. The neurology and natural history of patients with intermediate CAG repeat length mutations of the Huntington disease. J Neurol Sci 2011, 301:14-20.
28. Cheng W.C., Shu W.Y., Li C.Y., Tsai M.L., Chang C.W., et al. Intra and inter-individual variance of gene expression in clinical studies. PloS ONE 2012, 7:e38650.
29. Gershoni-Baruch R., Brik R., Shinawi M., livneh A. The differential contribution of MEFV mutant alleles to the clinical profile of familial Mediterranean fever. Eur J Hum Genet 2002, 10:145-149.
30. Tripathi S., Schultz I., Kraft T., et al. Unequal allelic expression of wild-type and mutated B-myosin in familial hypertrophic cardiomyopathy. Basic Res Cardiol 2011, 106(6):1041-1055.
31. Griffiths AJF, Miller JH, Suzuki DT et al. An introduction to genetic analysis, 7th edition New York; W.H. Freeman, 2000. Penetrance and expressivity. Available from http://www.ncbi.nlm.nih.gov/books/bk22090/.
32. Mac Arthur D.G., Balasubramanian S., Frankish A., Huang N., Morris J., et al. A systematic survey of loss-of-function variants in human protein-coding genes. Science 2012, 335:823-828.
33. Wolff A.P., Metzke M.A. Epigenetics, regulation though repression. Science 1999, 286(5439):481-486.
34. Fraga M.F., Esteller M. Towards the human cancer epigenome: a first draft of histone modifications. Cell Cycle 2005, 4(10):1377-1381.
35. Montesanto A., Dato S., Bellizzi D., Rose G., Passarino G. Epidemiological, genetic and epigenetic aspects of the research on healthy aging and longevity. Immunity Aging 2012, 9:6.
36. Lovrecic L, Maver A, Zadel M, Peterlin B. The role of epigenetics in neurodegenerative diseases. 2013. http://creativecommons%20org/licences/by/30.
37. Robinson R.L., Carpenter D., Halstall P.J., Iles D.E., Booms P., et al. Epigenetic silencing of variable penetrance of malignant hyperthermia susceptibility. Br J Anaesth 2009, Doi: 1093/bja.bja/aep 408.
38. Galatzka D., Hansmann T., El Hajj N., Weis E., Irmscher B., et al. Monozygotic twins discordant for constitutive BRCA1 promotor methylation, childhood cancer and secondary cancer. Epigenetic 2012, 7:47-54.
39. Shirahama S., Miyahara A., Kitoh H., Honda A., Kawase A., et al. Skewed x-chromosome inactivation causes intra-familial phenotypeic X-chromosome inactivation causes intrafamilial phenotypic variation of an EBP mutations in a family with x-linked dominant chondrodysplasia. Punctata 2003, 112:78-83.
40. Herrera BM, Keildson S, Lindgren CM. Genetics and epigenetics of obesity. www.ncbi.nlm.nih.gov/pmc/articles/pmc 3213306/.
41. Hunter D.J. Gene-environment interaction in human diseases. Nat Rev Genet 2005, 6:287-298.
42. Van Sponsen F.J. Phenylketonuria: a 21st century perspective. Nat Rev Endocrinol 2010, 6:502-514.
43. Barbieri M., Rizzo M.R., Papa M., Acampora R., et al. Role of interaction between variants in the PPARG and interleuken-6 gene on obesity related metabolic risk. Exp Gerontol 2005, 40:599-604.
44. Kilpelainen T.O., Qi L., Brage S., Sharp S.J., Sonestedt E., et al. Physical activity attenuates the influence of FTO variants on obesity risk: a meta-analysis of 218, 166 adults and 19,268 children. PloS Med 2011, 8:e100116.
45. O'Gorman C., Lucas R., Taylor B. Environmental risk factors for multiple sclerosis: a review with a focus on molecular mechanisms. Int J Mol Sci 2012, 13:11718-11752.
46. Cook J.D., Davis B.J., Cai S., Barrett C., Conti C.J., Walker C.L. Interaction between genetic susceptibility and early-life environmental exposure determines tumor-suppressor-gene penetrance. PNAS 2005, 102(24):8644-8649.
47. Tyrrell J., Huikari V., Freahy R.M. Genetic variation in the 15q nicotinic acetylcholine receptor gene cluster (CHRNA5- CHRNA3- CHRNB4) interacts with maternal self-reported smoking status during pregnancy to infleunce birth weight. Hum Mol Genet 2012, 15(24):5344-5358.
48. Brennan P., Hainant P., Boffetta P. Genetics of lung cancer susceptibility. Lancet Oncol 2011, 12:399-408.
49. Caspi A., McClay J., Moffitt T.E., Mill J., Martin J., et al. Role of genotype in the cycle of violence in maltreated children. Science 2002, 797(5582):851-854.
50. Page S.P., Kounas, Syrris P., Christiansen M., Frank-Hansen R., Andersen P.S., et al. Cardiac myosin binding protein-C mutations in families with hypertrophic cardiomyopathy: disease expression in relation to age, gender and longterm outcome. Circ Cardiovasc 2012, 5:156-166.
51. Stutzman F., Tan K., Vatin V., Dina C., Jouret B., et al. Prevalence of melanocortin - 4 receptor deficiency in European and their age-dependent penetrance in multigenerational Pedigree. Diabetes 2008, 57:2511-2518.
52. Smith BN, Topps, Barnwell J, Al-Chalabi A, Kirby J, et al., Age dependent penetrance of ALS +/-FTD due to C9 or f72 hexanucleotide intronic report expansion mutations www.ashg.org/2012 meeting/abstracts/fulltext/f /2012.
53. Antonion A., Pharoah P.D., Narods, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003, 72(5):1117-1130.
54. Al-Mulla F., Bland J.M., Serratt D., Miller J., Chu C., Taylor G.T. Age-dependent penetrance of different germline mutations in the BRCA1 gene. J Clin Pathol 2009, 62(4):350-356.
55. Ruiz-Martinez J., Gorostide A., Ibanez B., et al. Penetrance in Parkinson's disease related to the LRRK2 R1441G mutation in the Basque country (Spain). Mov Disord 2010, 25:2340-2345.
56. Hellman U., Alarcon F., Lundgren H.E., Suhr O.B., Bonoiti-Pellie' C., et al. Heterogeneity of penetrance in familial amyloid polyneuropathy, ATTR Val 30 Met, in the Swedish population. Amyloid 2008, 15:181-186.
57. Coleman WB, Tsongalis GJ. Essential concepts of molecular pathology, 2010, Academic Press Feb. 16, 2010, page 70.
58. Ke Q., Luo B., Qi M., Du Y., Wu W. Gender differences in penetrance and phenotype in hypokalemic periodic paralysis. Muscle Nerve 2013, 47:41-45.
59. Muller B., Hedrick K., Kock N., Dragasevic N., Svetel M., Garrels J., et al. Evidence that paternal expression of the epsilon-sarcoglycan gene accounts for reduced penetrance in myoclonus-dystonia. Am J Hum Genet 2002, 71:1303-1311.
60. Michael C.R., Alavanja DrPH., Mathew K., et al. Increased cancer burden among pesticide applicators and others due to pesticide exposure. CA. A Cancer J Clinicians 2012, 63(2):120-142.
61. Zhang W., Bleibel W.K., Roe C.A., Cox N.J., Dolan M.E. Gender specific differences in expression in human lymphoblastoid cell lines. Pharmacogenet Genomics 2007, 17:447-450.
62. Vogel F., Motulsky A.G. Human Genetics. Problems and Approaches 1997, Springer, Berlin. third ed.
63. Basel-Vangaite L., Pelet A., Steiner Z., Munnich A., et al. Allele dosage-dependent penetrant of RET proto-oncogene in an Israeli-Arab Inbred family segregating Hirschsprung disease. Eur J Hum Genet 2007, 15:242-245.
64. Flanagan N., Healy E., Ray A., Philips S., Carole T., et al. Pleotrophic effects of the melanocortin 1 receptor (MCIR) gene on human pigmentation. Hum Mol Genet 2000, 9(17):2531-2537.
65. Pereira A.C., Mota G.F.A., Cunha R.S., Herbenhoff F.L., Mill J.G., Krieger J.E. Angiotensinogen 235T allele "dosage" is associated with blood pressure phenotype 2003, 41:25-30.
66. Hoefele J., Wolf M.T.F., D'Toole J.F., Otto E.A., et al. Evidence of oligogenic inheritance in nephronophthisis. J Am Soc Nephrol 2007, 18(10):2789-2795.
67. Chakravarti A., Lyonnets S. The Metabolic and Molecular Basis of Inherited Disease 2001, McGraw-Hill, New York.
68. Gabriel S.B., Salomon R., Pelet A., Angrist M., Amiel J., et al. Segregation of three loci explains familial and population risk in Hirschsprung disease. Nat Genet 2002, 31:89-93.
69. Muenke M., Beachy P.A. The Metabolic and Molecular Basis of Inherited Disease 2001, McGraw-Hill, New York.
70. Abu-Safieh L., Al-Anazi S., Al-Abdi L., Hashem M., et al. In search of triallelism in Bardet-Biedle syndrome. Eur J Hum Genet 2012, 20:420-427.
71. Dibbens L.M., Heron S.E., Mully J.C. A polygenic heterogeneity model for common epilepsies with complex genetics. Genes Brain Behav 2007, 6:593-597.
72. Fechtel K., Osterbur M.L., Kehrer-Sawatzki H., Stenson P.D., et al. Delineating the hemostaseome as an aid to individualize the analysis of the hereditary basis of thrombotic and bleeding disorders. Hum Genet 2011, 130:149-166.
73. Marras C., Klein C., Lang A.E., Wakutani Y., Moreno D., et al. LRRK2 and Parkin mutations in a family with parkinsonism - lack of genotype-phenotype correlation. Neurobiol Aging 2010, 31:721-722.
74. Pitteloud N., Quinton R., Crowley W., et al. Digenic mutations account for variable phenotypes in idopathic hypogonadotrophic hypogonadism. J Clin Invest 2007, 117(2):457-463.
75. Schaffer N.A. Digenic inheritance in medical genetics. J Med Genet 2013, Doi: 10.1136/jmedgenet-2013-101713.
76. Kajiwara K., Berson E.L., Dryja T.P. Digenic retinitis pigmentosa due to mutations at the unlinked peripherin/RDS and ROM1 Loci. Science 1994, 264:1604-1608.
77. Ekvall S., hagenas L., Allanson J., anneren G., Bondeson M.L. Co-occurring SHOC2 and PTPN11 mutations in patients with severe, complex Noonan syndrome-like phenotype. Am J Med Genet 2011, 155A:1217-1224.
78. Agarwal S., Moorchung N. Modifier genes and oligogenic disease. N Nippon Med Sch 2005, 72(6):326-346.
79. Khalid A., Finkelstein S., Thompson B., Kelly L., Hunk C., et al. A 93 year old man with the PRSSI R 122H mutation, low SPINKI expression, and no pancreatitis: insight into phenotype non penetrance. Gut 2009, 55:728-731.
80. Daw E.W., Chen S.N., Czernuszewicz G., Lombardi R., Lu Y., et al. Genome-wide mapping of modifier chromosomal loci for human hypertrophic cardiomyopathy. Hum Mol Genet 2007, 16:2463-2471.
81. Riazuddin S., Castelein C.M., Ahmed Z.M., La Lwani A.K., et al. Dominant modifier DFNMI suppresses recessive deafness, DF NB26. Nat Genet 2000, 26:431-434.
82. Badano J.I., Katsanis N. Beyond Mendel: an evolving view of human genetic disease transmission. Nat Rev Genet 2002, 3:779-789.
83. Boyle M.P. Strategies for identifying modifier gene in cystic fibrosis. Proceedings of the American Thoracic Society 2007, 4(1):52-57.
84. Davies J.C., Turner M.W., Klein N. Impaired pulmonary status in cystic fibrosis adults with two mutanted MBL-2 alleles. Eur Respir J 2004, 24:798-804.
85. Frangolias D.D., Ruan J., Wilcox P.J., Dadidson A.G., et al. Alpha 1-antitrypsin deficiency alleles in cystic fibrosis lung disease. Am Respir Cell Mol Biol 2003, 29:390-396.
86. Buscher R., Eilmes K.J., Grasemann H., Torres B., Knayer N., et al. Beta-2 adrenoreceptor gene polymorphisms in cystic fibrosis lung disease. Pharmacogenetics 2002, 12:347-353.
87. Baranov V.S., Ivaschenko T., Bakay B., Aseev M., et al. Proportion of GSTM1 0/0 genotype in some slavic populations and its correlation with cystic fibrosis and some multifactorial diseases. Hum Genet 1996, 97:516-520.
88. Grasmann H., Storm Van's G.K., Buscher R., Knaeer N., Silverman E.S., Palmer I.J., et al. Endothelial nitric oxide synthase variants in cystic fibrosis lung disease. Am J Respir Crit care Med 2003, 167:390-394.
89. Mckone E.F., Shao J., Frangolias D.D., Keener C.L., et al. Variants in the glutamate-cysteine-ligase gene are associated with cystic fibrosis lung disease. Am J Respir Crit Care Med 2006, 174:415-419.
90. Jeri I., Hayrapetyan H., Duquesnoy P., Cochet E., et al. Involvement of the modifier gene of a human Mendelian disorder in a negative selection process. Plos ONE 2009, 4(10):e7676.
91. Bassett A.S., Scherer S.W., Brzustowicz L.M. Copy number variations in schizophrenia: critical review and new perspectives on concepts of genetics and disease. Am J Psychiatry 2010, 167:899-914.
92. Carvill G.L., Mefford H.C. Microdeletion syndromes. Curr Opin Genet Develop 2013, 23:1-8.
93. Carvalho CMB, Bartnik M, Lupski JR, et al. Evidence of disease penetrance relating to CNV size: Pelizaeus-Merzbacher disease and manifesting carriers with familial 11Mb duplication at Xq 22 http://www.ncbi.nlm.gov/pmc/aticles/PMC3470482/.
94. Mintz M. Functional impact of global rare copy number variation in autism spectrum disorders. www. Cnnh.org/functional-impact - of - global-rare-copy-number-variation - in-autism-spectrum disorders/.
95. Tropeano M., Ahn J.W., Dobson R.J.B., Breen G., Rucker J., et al. Male-Biased autosomal effects of 16p 13.11 copy number variation in Neurodevelopmental disorders. PLoS ONE 2013, 8(4):e61365.
96. Lacaria M, Saha P, Potocki L, Bi W et al. A duplication CNV that conveys Traits Reciprocal to Metabolic Syndrome and Protects against Diet-Induced Obesity in Mice and Men. Plos Genetics, 2012, Doi: 10.1371/Journal.Pgen.102713.
97. Girirazan S., Rosenfeld J.A., Coe B.P., Parikh S., Friedman N., Goldstein A., et al. Phenotypic heterogeneity of genomic disorders and rare copy number variants. New Engl J Med 2012, 367:1321-1331.
98. Wirth B., Brichta L., Schrank B., Loch muller H., Blick S., et al. Mildly affected patients with spinal muscular atrophy are partially protected by an increased SMN2 copy number. Hum Genet 2006, 119:422-428.
99. Buckland P.R. Allele-specific gene expression differences in humans. Hum Mol Genet 2004, 13(2):R 255-R 260.
100. Fairwether-Tait S.J., Harvey L., Heath A.L.M., Roe M. Effect of SNPs on iron metabolism. Genes Nutr 2007, 2:15-19.
101. Menon S., Cox H.C., Kuwahata M., Quinlan S., Mac Millan J.C. Association of a Notch 3 gene polymorphism with migraine susceptibility. Cephalalgia 2011, 31(3):264-270.
102. Fransen K., Visschedjk M.C., Sommeren S.V., Fu J.Y., Frank L., et al. Analysis of SNPs with an effect on gene expression identifies UBE 2L3 and BCL3 as potential new risk genes for crohn's disease. Hum Mol Genet 2010, 19(17):3482-3488.
103. Crotti L., Lundquist A.L., Insolia R., Pedrazzini, et al. KCNH2-K897T is a genetic modifier of latent congenital long-QT syndrome circulation 2005, 112:1251-1258.
104. Snozek C.L., Lagerstedt S.A., Khoo T.K., Rubenfire M., et al. LDLR promoter variant and exon 14 mutation on same chromosome are associated with an unusually severe FH phenotype and treatment resistance. Eur J Hum Genet 2009, 17:85-90.